Compare NUVL & PDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUVL | PDI |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 7.6B |
| IPO Year | 2021 | N/A |
| Metric | NUVL | PDI |
|---|---|---|
| Price | $103.39 | $18.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $135.00 | N/A |
| AVG Volume (30 Days) | 581.9K | ★ 1.5M |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.81% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $55.54 | $15.45 |
| 52 Week High | $113.02 | $19.60 |
| Indicator | NUVL | PDI |
|---|---|---|
| Relative Strength Index (RSI) | 48.27 | 59.73 |
| Support Level | $100.19 | $18.02 |
| Resistance Level | $107.51 | $18.17 |
| Average True Range (ATR) | 4.89 | 0.08 |
| MACD | -0.41 | 0.01 |
| Stochastic Oscillator | 36.14 | 78.85 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
PIMCO Dynamic Income Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek current income. Its secondary objective is to seek capital appreciation. The fund invests world-wide in a portfolio of debt obligations and other income-producing securities with varying maturities and related derivative instruments. Its investment portfolio includes mortgage-backed securities, investment-grade, and high-yield corporates, corporate and sovereign bonds, other income-producing securities, and related derivative instruments.